Decoy Therapeutics Inc. (DCOY)
| Market Cap | 1.75M -25.1% |
| Revenue (ttm) | 227,629 |
| Net Income | -14.45M |
| EPS | -40.40 |
| Shares Out | 655.19K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,741 |
| Open | 2.752 |
| Previous Close | 2.730 |
| Day's Range | 2.600 - 2.776 |
| 52-Week Range | 2.600 - 70.800 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About DCOY
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design α-helical peptides through computational and ML tools. The company’s IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting ... [Read more]
Financial Performance
Financial StatementsNews
Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Rick Pierce, Chief Executive Officer, to deliver an investor presentation on Thursday, September 10 in New York Cambridge, Massachusetts--(Newsfile Corp. - September 8, 2026) - Decoy Therapeutics, Inc...
Decoy Therapeutics Quarterly report: Q2 2026
Decoy Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on August 4, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on August 4, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the de...
Decoy Therapeutics’ D-MAV platform shows inhibition of Ebola Zaire virus
Decoy Therapeutics (DCOY) announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building ...
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Lead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new program in filovirus pandemic preparedness CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Thera...
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on July 24, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineere...
Decoy Therapeutics registers to sell 3.77M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.77M shares of common stock. The company is not selling any…
Decoy Therapeutics Registration statement: Registration filing
Decoy Therapeutics filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
Why Is Penny Stock Decoy Therapeutics (DCOY) Up Today?
Decoy Therapeutics stock rallied on Monday alongside news of new funding for the company.
Decoy Therapeutics Inc trading resumes
09:36 EDT Decoy Therapeutics (DCOY) Inc trading resumes
Decoy Therapeutics Inc trading halted, volatility trading pause
09:31 EDT Decoy Therapeutics (DCOY) Inc trading halted, volatility trading pause
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of a...
Decoy Therapeutics Registration statement: Registration filing
Decoy Therapeutics filed a registration statement on June 15, 2026, providing details about a securities offering with the SEC.
Decoy Therapeutics files to sell 808,000 shares of common stock for holders
06:13 EDT Decoy Therapeutics (DCOY) files to sell 808,000 shares of common stock for holders
Decoy Therapeutics Inc trading resumes
11:52 EDT Decoy Therapeutics (DCOY) Inc trading resumes
Decoy Therapeutics Inc trading halted, volatility trading pause
11:42 EDT Decoy Therapeutics (DCOY) Inc trading halted, volatility trading pause
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- Decoy Therapeut...
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on June 4, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on June 4, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered...
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic CAMBRIDGE, Mass., June 1,...
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development NEW YORK and CAMBRIDGE, Mass., May 26, 2026 /PRNewswire/ -- Decoy Therap...